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O cérebro é uma estrutura complexa, que é composta por neurónios capazes 
de comunicar através de sinapses. Estas normalmente ocorrem entre um 
terminal axónico e espinha dendritica de neurónios diferentes. As espinhas 
dendriticas são estruturas dinâmicas que permitem uma rápida adaptação a 
diferentes estímulos. A PP1 é uma proteína fosfatase que catalisa a maioria das 
desfosforilações que ocorrem no corpo humano. Tem diversas funções, que 
variam desde metabolismo de glicogénio a regulação sináptica. As neurorabinas 
(1 e 2) são duas subunidades reguladores da PP1 que são estruturalmente e 
funcionalmente idênticas entre si. São muito enriquecidas nas espinhas 
dendriticas e interagem com diversas proteínas, incluindo a PP1, e guiam as 
proteínas para receptores, citoesqueleto ou outros compartimentos celulares,  
regulando assim a morfologia neuronal e transmissão e plasticidade sináptica. 
A Phactr3 pertence à família de proteínas reguladoras de actina, á qual 
pertencem quatro membros. A Phactr3 está envolvida na migração celular e 
regula a dinâmica do citoesqueleto. Interage com a PP1, formando um complexo 
que é controlado por alterações na concentração de G-actina citoplasmática, 
regulando assim a dinâmica do citoesqueleto. Doenças neurodegenerativas, 
são normalmente caracterizadas pela perda de sinapses, morte neuronal, e 
perda gradual de funções cognitivas e memória. Acredita-se que o principal fator 
responsável por essas anomalias seja o péptido Aβ. Este resulta de uma 
clivagem anormal de APP, pela via amiloidogénica, resultando numa 
sobreprodução do péptido tóxico.  
O objectivo desta tese era avaliar os efeitos de Aβ nos níveis de expressão das 
neurorabinas e Phactr3, assim como os complexos formados com a PP1. Os 
resultados mostram uma ligeira diminuição nos níveis de expressão das 
neurorabinas, e num ligeiro aumento na expressão de Phactr3. Os resultados 
também mostram uma diminuição na interação do complexo Neurorabina-
1/PP1, provavelmente devido a um efeito direto de Aβ sobre Neurorabina-1 ou 
um desequilíbrio nas fosfatases e cinases, e Phactr3/PP1, provavelmente 
devido a variação nos níveis de G-actina, que compete com a PP1 para interagir 
com Phactr3. As mesmas alterações não foram verificadas no complexo 
Neurorabina-2/PP1. Uma explicação possível é que ambas as proteínas são 
reguladas de forma diferente por diversas cinases. Estes resultados permitem 
concluir que Aβ interfere na expressão das três proteínas e nos níveis de 
interação de Neurabina-1/PP1 e Phactr3/PP1. No entanto são necessários mais 
estudos para obter uma melhor compreensão da relevância fisiológica destes 
complexos. 
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abstract 
 
The brain is a complex structure, which is comprised by neurons capable of 
communication through synapses. These usually occur between an axon 
terminal and a dendritic spine of different neurons. The dendritic spines are 
dynamic structures that allow for a rapid adaptation to different stimuli. PP1 is a 
phosphatase protein that catalyses the majority of dephosphorylation reactions 
in the human body. It has different functions that vary, from glycogen metabolism 
to synaptic regulation. Neurabins (1 and 2) are two PP1 regulator subunits that 
are structurally and functionally similar to each other. They are highly enriched 
in the dendritic spines, interacting with several proteins, including PP1, and 
targeting them to receptors, cytoskeleton or other cellular compartments. Thus, 
regulating neuronal morphology and synaptic transmission and plasticity. 
Phactr3 belongs to the actin regulatory protein family, which comprises four 
members. Phactr3 is involved in cell migration and regulates cytoskeleton 
dynamics. It interacts with PP1 forming a complex that is controlled by changes 
in cytoplasmic G-actin concentration, thus, regulating actin cytoskeleton 
dynamics. Neurodegenerative diseases are usually characterised by the loss of 
synapses, neural death, gradual loss of cognitive functions and memory. It is 
believed that Aβ is the major culprit in these changes. Aβ results from an 
abnormal cleavage of APP, via the amyloidogenic pathway, resulting in the 
overproduction of toxic peptides.  
The main aim of this thesis was to evaluate the effects of Aβ on Neurabins and 
Phactr3 expression, and in PP1 complexes. The results show a slight decrease 
in neurabins’ expression, and a slight increase in Phactr3 expression. The results 
also show a decrease in interaction between PP1 and Neurabin-1, possibly due 
to direct effect of Aβ on Neurabin-1 or the imbalance of phosphatases and 
kinases, and between PP1 and Phactr3, possibly due to variations of G-actin 
levels which competes with PP1 to binding with Phactr3. The same changes 
were not observed in Neurabin-2/PP1 complexes. A possible explanation is that 
both are differently regulated by several kinases.  
The results allow us to conclude that Aβ interferes in the expression of all three 
proteins and in the interaction of Neurabin-1/PP1. However, additional studies 
are required in order to better understand the physiological relevance of these 
complexes.  
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1. Introduction         
1.1. The human brain and neuronal cells 
The human brain is a highly complex structure, which governs our lives. It 
dictates everything that we do, think and feel. It commands all our actions, thoughts, 
memories and emotions. To guarantee that its functions are properly executed, the 
brain needs a highly organized network.1–3 
The brain network includes an elaborate neuronal matrix, capable of 
communication, through neuronal synapses.4,5 Most synapses are chemical, and rely 
on transferring endogenous chemical compounds, called neurotransmitters, between 
neurons. The neurotransmitters are produced in the presynaptic neuron and 
encapsulated within synaptic vesicles, that are secreted to the synaptic cleft.6 After 
diffusion through the synaptic cleft, neurotransmitters bind to specific receptors on the 
membrane of the postsynaptic neuron.7  
 
Figure 1 - Chemical Synapse, taken from60. 
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1.2. Dendritic Spines 
Dendritic spines are the morphologic correlates of excitatory post synapses8. They 
are tiny, bulbous structures that protrude from the dendrites in neurons and receive fast 
excitatory synaptic input in the brain.9 This type of neuronal communication usually occurs 
between an axon terminal (presynaptic component) and dendritic spines (post synaptic 
component). These structures, compartmentalize the postsynaptic machinery and 
biochemical signaling molecules needed to respond to input from single presynaptic 
terminals. It is now widely accepted that this compartmentalization serves a major function 
of spine structure: input specificity of synaptic plasticity10.  
Dendritic spines are present on different populations of neurons in the brain and 
are preferentially located on the peripheral dendrites of neocortical and hippocampal 
pyramidal neurons, on the striatum and in cerebellar Purkinje cells. They are thought to be 
key structures in both learning and memory formation, as they receive the majority of 
excitatory and inhibitory outputs in the central nervous system.11 
1.2.1. Structure and composition 
Morphologically, spines are specialized protrusions from a dendrite’s shaft, where 
neurons form synapses to receive and integrate information and can be classified into three 
major types: Mushroom spines, which have a large head and a thin neck; stubby spines, 
which have a large head but no discernible neck; and thin spines, which are slender without 
a discernible head8,9,11,12. 
Figure 2 - Dendritic spine morphology. Circle, thin dendritic spine;  Arrow, Mushroom dendritic spine; Triangle, 
Stubby dendritic spine. Taken from61. 
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However, dendritic spines are not static, i.e., they do not always have the same 
structure, since in developing neurons, the majority of dendritic spines change their shape 
over periods of minutes to hours. As for dendritic spines in mature neurons, they are not 
as motile as in developing neurons and thus, there are fewer changes in their shape. Large 
spines are functionally stronger in their response to glutamate, regulation of intracellular 
calcium, protein translation and degradation, and endosomal recycling than smaller spines, 
which are more flexible, rapidly enlarging or shrinking in response to subsequent 
activation. 9,11 
The first structure of the dendritic spine, and probably the most complex spine 
organelle, is the postsynaptic density (PSD), an electron-dense thickening of the 
postsynaptic membrane that harbors hundreds of proteins involved in synaptic plasticity, 
including neurotransmitter receptors, such as N-methyl-D-aspartate (NMDA) receptors, α-
amino-3-hydroxy-5-methyl-4-isoxazole propionic (AMPA) receptors, kainate and 
metabotropic glutamate receptors, along with numerous signaling and scaffolding 
proteins. 6,9,11,13 
 
Below the PSD we can find both monomeric (globular, g-actin) and filamentous (F-
actin) actin. The spines’ cytoskeleton is rich in f-actin, which modulates spine head 
structure in response to postsynaptic signaling and contributes to the overall structure of 
synapses. It organizes the PSD, anchoring and stabilizing postsynaptic receptors and 
localizing the translation machinery.11 The dendritic spine is rich in actin-binding proteins, 
actin-associated proteins and some small GTPases that cooperate to regulate actin-based 
cellular events, such as the formation, elimination, motility, stability, size and shape of 
dendritic spines14. This actin cytoskeleton helps explain why a variety of dendritic spines 
exist, since actin is very dynamic and allows for changes in size and shape of dendritic 
spines.9,14 
Additionally, several other organelles can be found within dendritic spines, such as 
the smooth endoplasmic reticulum, a spinae apparatus, clusters of polyribosomes and 
proteasomes.  
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1.2.2. Dendritic Spine formation 
 
There are three main views on the origin of dendritic spines, which imply different 
molecular mechanisms of spine origin. The first model states that once dendritic filopodia, 
predominant in younger neurons, establish synaptic contact they originate dendritic 
spines. This model is based on the fact that, as synapses form, the number of filopodia 
declines and the number of spine-like structures increase, which may suggest that filopodia 
are the precursors of dendritic spines. So, this model suggests that the highly motile 
filopodia act as a probe that search for appropriate contacts. The axon guidance (suggested 
by the fact that release of glutamate from sites of presynaptic vesicle release, promotes 
filopodia extension) and cell adhesion molecules present on developing dendrites and 
axons may contribute to directing the movements of filopodia and their selective adhesion 
to a compatible axonal partner.15 
The second model proposes that dendritic spines arise from synapses that are 
initially formed on the dendritic shaft. This view is supported by the observation that most 
synapses in younger pyramidal neurons are located on the dendritic shaft rather than on 
filopodia.16 
The third model states that spines can form even without synaptic contact. Spines 
of the distal dendritic branches of cerebellar Purkinje neurons form before the 
establishment of synaptic contact with the presynaptic parallel fibers. 16 
Since these three models base their assumptions on different types of neurons, it is 
more likely that dendritic spines emerge through different mechanisms depending on the 
type of neuron. However, it has also been proposed that these three models might be part 
of the same process, which occur in specific temporal periods of a neuron’s life and may be 
dependent on the maturation of filopodia and dendritic spines. 15,16 
Following genesis of dendritic spines, they pass through a process of maturation 
where there is an increase in spine density, a decrease in overall length and a decrease in 
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the number of dendritic filopodia with a simultaneous decrease in spine motility. This 
maturation process also results in synapse maturation, which involves the further 
recruitment of presynaptic and postsynaptic components (scaffolding proteins and 
neurotransmitters receptors, for example). 12 
Finally, after maturation of dendritic spines and formed synapses, there is a 
retraction of some contacts and elimination of inappropriate synaptic proteins, which 
refine the neuronal circuitry, together with long-term potentiation (LTP) and long-term 
depression (LTD). 9,11 
 
1.2.3. Synaptic plasticity 
Synaptic plasticity is the ability that neurons have to positively or negatively change 
the efficacy of their connections in response to neuronal activity. This synaptic connectivity 
is dynamic, constantly changing in response to neural activity and other influences, and can 
vary in time from milliseconds to years. 17 
Short-term synaptic plasticity includes facilitation, augmentation, potentiation and 
synaptic depression. Synaptic facilitation is a rapid increase in synaptic strength that occurs 
when two or more action potentials invade the presynaptic terminal within a few 
milliseconds of each other.5 Synaptic augmentation of potentiation is also elicited by 
repeated synaptic activity and serves to increase the amount of neurotransmitters released 
from presynaptic to postsynaptic terminals. Synaptic depression opposes facilitation, 
causing a decline in neurotransmitter release during sustained synaptic activity. 17 
Long-term synaptic plasticity includes LTP (long-term potentiation) and LTD (long-
term depression). LTP is a long-lasting increase in synaptic strength due to certain patterns 
of high frequency electrical stimulation, whereas LTD is a long-lasting decrease in synaptic 
strength due to certain patterns of low frequency electrical stimulation, both of which are 
thought to be important for memory formation and storage in the brain. LTP and LTD are 
intimately related with the neuronal F-actin cytoskeleton. LTP can result in spine head 
enlargement accompanied by an increase in F-actin levels, whereas LTD results in shrinkage 
of dendritic spine heads and even spine elimination, which is accompanied with actin 
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depolymerization. Thus, the g-actin/f-actin ratio and all the proteins that can interfere with 
the former affect the various aspects of dendritic spine morphology and consequently, 
synaptic plasticity.9 
These enduring forms of synaptic plasticity lead to protein phosphorylation and 
changes in gene expression which greatly outlast the period of synaptic activity and can 
yield changes in synaptic strength that persist for hours, days, or even longer5. It is an 
important neural mechanism, which modulates several forms of brain plasticity, such as 
learning new behaviors or acquiring new memories. 11 
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1.3. PP1  
Protein phosphatase 1 (PP1) is a serine/threonine (Ser/Thr) phosphatase that 
belongs to the phosphoprotein phosphatase superfamily along with PP2A, PP2B, PP4, PP5, 
PP6 and PP7. These phosphatases catalyze over 90% of all eukaryotic protein 
dephosphorylation reactions and among them, PP1 is the most important one in terms of 
substrate diversity, with close to 400 PP1-interacting proteins (PIPs) already identified.18,19 
PP1 is known to be involved in glycogen metabolism, transcription, protein 
synthesis, cellular division, meiosis and apoptosis. Additionally, through interaction with its 
regulatory proteins, PP1 can be involved in neurotransmission, neurite outgrowth and 
synapse formation20.  
This versatility of PP1 is largely determined by the binding to different specific 
regulatory subunits, which can function as inhibitors of its activity, substrate-specifying 
subunits, targeting subunits or substrates. By interacting with its substrates, PP1 can 
dephosphorylate them at a single or multiple residue, activating or inactivating them18. 
Some proteins can also mediate the targeting of PP1 to specific protein complexes, bringing 
PP1 near to specific substrates21,22. PP1 can also interact with proteins which enhance its 
activity towards a specific substrate, such as myosin phosphate-targeting subunit 1 
(MYPT1)23. Additionally, some proteins, such as dopamine and cAMP-regulated neuronal 
phosphoprotein (DARPP-32) and inhibitors-1/2/3, can directly block PP1 activity, thus 
inhibiting the dephosphorylation of all PP1 substrates. 21 
 
1.3.1. PP1 isoforms 
The mammalian genome contains three different genes for PP1 (PP1CA, PP1CB and 
PP1CC) that encode four distinct catalytic subunits: PP1α, PP1β and the splice variants 
PP1γ1 and PP1γ2.18 
PP1α, PP1β and PP1γ1 are ubiquitously expressed, while PP1γ2 isoform is testis-
enriched and sperm-specific. Even though PP1α, PP1β and PP1γ1 are ubiquitously 
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expressed, their expression levels differ, depending on the cell type and tissue24. For 
instance, PP1α is more enriched in the brain (especially in the striatum and hippocampus) 
and in the heart; PP1β is more enriched in the brain, small intestine, muscle and lung; and 
PP1γ1 is more enriched in the brain (especially in the striatum and hippocampus), heart 
and skeletal muscle. Additionally, even in the same cell type, isoforms have distinct 
localizations. In neuronal cells, PP1α is specially localized in dendritic spines, PP1β to the 
soma and dendritic shaft, and PP1γ1 to the dendritic spines and presynaptic terminals25.  
 
 
1.3.2.  PP1 Docking Motifs 
 
As previously mentioned, PP1 has nearly 200 validated PIPs and by using 
bioinformatic-assisted PIP identification screens it is estimated that hundreds more PIPs 
remain to be identified and validated. Moreover, PIPs interact with PP1 unique binding 
motifs, such as RVxF, SILK, MyPhoNE, SpiDoC, IDoHA and others.18 
Among these binding motifs, the RVxF motif is the most common, being present in 
nearly 70-90% of all validated PIPs. This motif generally conforms to the consensus 
sequence [K/R] [K/R][V/I][x][F/W], with x being any reside other than Phe, Ile, Met, Tyr, Asp 
or Pro. Interaction between PIPs and PP1 through this motif does not change PP1 
conformation and only serves to anchor the PIPs to PP1, bringing them closer to PP1 and 
promoting secondary interactions that determine the activity and substrate specificity of 
PP1. 18,26,27 
The SILK motif, [GS]IL[KR], initially described as being essential to PP1 inhibition by 
inhibitor-2, is present in seven PIPs and, as the RVxF motif, seems essentially for PP1 
anchoring18,28. The MyPhoNE motif, RxxQ[VIL][KR]x[YW], is present in seven PIPs and is 
involved in substrate recognition. Both motifs are always N-terminal to the RVxF. 18,28,29 
SpiDoC, is a domain in neurabin-2 which binds to the PP1 C-terminal groove, 
blocking access to substrates that require this groove for PP1 binding, thus directing the 
substrate specificity of PP1. 18,23 
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Aside from the RVxF and the SILK motif (Figure 3), inhibitor-2 has a third motif able 
to interact with PP1 – IDoHA. This motif binds PP1 in a manner that covers its active site, 
preventing PP1 activity. 18  
 
1.4. Neurabins 
1.4.1. Neurabin 1 
Neurabin-1 is a multifunctional scaffolding protein first identified and characterized 
in 1997 from purified rat brain tissue. The human neurabin-1 is encoded by the PPP1R9A 
gene (protein phosphatase 1, regulatory subunit 9A) located on chromosome 7 and is 
comprised of 1098 amino acids (a.a.). It has an N-terminal F-actin binding domain (a.a. 1-
144), followed by a PP1 binding domain (a.a. 425-502), a PDZ (PSD-95/Dlg/ZO-1) domain 
(a.a. 504-592), three C-terminal coiled-coil regions (a.a. 597-627, a.a. 670-824, 1033-1090) 
and a sterile alpha motif (SAM) domain (a.a. 988-1051). These two latter domains are 
known to mediate homo- and heterodimerization of other proteins. Within the PP1-binding 
domain it is possible to identify a KIKF motif, conserved in other PP1 regulatory subunits. 
Figure 3 - PP1 docking motifs RVxF, SILK, MyPhoNE, SpiDoC and IDoHA. PIPs combine PP1 docking sites to form unique 
PP1 holoenzymes. Taken from18. 
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Neurabin-1 also has some consensus sequences for phosphorylation by several protein 
kinases. 30 
Neurabin-1 is highly concentrated in the synapse and in the growth cone of 
developed and developing neurons, respectively31,32.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 – Neurabin – 2 domain Structure. Boxes represent the several domains found in both Neurabin-1 and 
Neurabin-2. Actin BD, Actin Binding Domain; PP1 BD, PP1 Binding Domain; PDZ, PSD-95/Dlg/ZO-1 
domain; CC, coiled-coil domain. Taken from42. 
 
 
Figure 4- Neurabin-1 domain structure. Boxes represent the several domains found in Neurabin-1. Actin BD, Actin 
Binding Domain; PP1 BD, PP1-binding Domain; PDZ, PSD-95/DLG/ZO-1 domain; CC, coiled-coil domain; SAM, sterile 
alpha motif. Taken from33. 
Neurabin II 
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1.4.2. Neurabin 2 
Neurabin-2, also known as Spinophilin, was initially identified and described in 1997 
due to its ability to form a complex with the catalytic subunit of PP1 and due to its potent 
modulation of PP1 enzymatic activity in vitro. In humans it is encoded by the PPP1R9B gene 
located on the chromosome 17 and is comprised of 817 amino acids. It has two F-actin-, a 
receptor- and a PP1-binding domain, a LIZ and a PDZ domain, and three coiled-coil 
domains33.  
The Neurabin-2 F-actin-binding domain (a.a. 1-154) is intrinsically unstructured, but 
upon binding to F-actin adopts a more ordered structure. Additionally, a second F-actin 
binding domain was described between a.a. 164-282. However, it is still unknown whether 
these two domains represent segments of a single domain or two independent domains33.  
The receptor-binding domain, located between a.a. 154-444, interacts with the 
third intracellular loop of various seven transmembrane domain receptors, such as the 
dopamine D2 receptor and some subtypes of the alfa-adregenic and muscarinic-
acetylcholine receptors33.  
The PP1 binding domains located within residues 417-494 contains the 
pentapeptide RKIHF motif between 447-451, and is conserved in other PP1 regulatory 
subunits. Within this domain it is possible to find other regions able to bind to PP123,33. A 
LIZ motif was described between a.a. 485-510, known to mediate protein-protein 
interactions and target protein kinases and protein phosphatases to membrane ion 
channels. The PDZ domain (a.a. 494-585) directly binds to C-terminal peptides derived from 
glutaminergic AMPA and NMDA receptors. The three-predicted coiled-coil domains 
between a.a. 664-814 allow for homo- hetero- dimerization between neurabin-2 and other 
proteins. Neurabin-2 also has some consensus phosphorylation sequences for  several 
protein kinases. 23,33 
Contrary to Neurabin-1, Neurabin-2 is ubiquitously expressed. It is highly 
concentrated in brain tissue, especially in neurons, where it is enriched in the PSD34.  
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1.5. Phactrs 
1.5.1. Phactr 3 
Protein phosphatase 1 (PP1) and actin regulatory (Phactr) proteins are a family 
that comprises four members in humans and other vertebrates; phactr1–4. Phactr-3 is 
diffusely expressed throughout the brain35. 
Each Phactr protein contains four G-actin-binding RPEL motifs, including an N-
terminal motif and a C-terminal triple RPEL repeat. The C-terminal triple RPEL repeat is 
adjacent to the PP1-binding domain. RPEL motifs are also found in the regulatory domains 
of myocardin-related transcription factor (MRTF) transcriptional coactivators where 
subcellular localization and activity is controlled by sensing signal-induced changes in the 
G-actin concentration36. 
Phactr family proteins are involved in cell migration both in vitro and in vivo, and it 
is believed that they regulate cytoskeleton dynamics37–39.  The Phactr protein family is 
considered to be involved in cell migration and morphogenesis by modulating the actin 
cytoskeleton. Phactr3 is distributed to the plasma membrane in adherent cells, and it 
enhances cell migration. This indicates that phactr3 is a membrane-associated PP1 and an 
actin regulator36,40.  
Phactr3 lacks fatty acid-attachment sites (e.g., palmitoylation, prenylation, and 
myristorylation sites) and lipid-binding domains with defined ternary structures (e.g., a PH 
domain)36. G-actin and PP1 competitively bind to the C-terminal regions of Phactr proteins 
and the cytoplasmic G-actin concentration is determined by RPEL motifs, which control the 
formation of the phactr-PP1 complex. With an increase in cytoplasmic G-actin levels the 
Phactr-PP1 complex is inhibited. Previous studies suggest that the phactr-PP1complex 
modulates the phosphorylation status of cofilin or myosin; therefore, regulating actin 
cytoskeleton dynamics. Overall, these results suggest that Phactr protein is a membrane-
associated PP1 regulator, which is itself regulated by signal-induced changes in the 
cytoplasmic G-actin levels. Therefore, it is likely that the Phactr-PP1 complex modulates 
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the phosphorylation status of actin cytoskeleton regulators such as cofilin and myosin, 
which associate with the plasma membrane36,40.  
 
 
 
Figure 6 -Phactr3 domain structure. Boxes represent the several domains found in Phactr3. NC, N-terminal region that 
is conserved in the Phactr family; PR, the proline-rich region; RPEL, the three tandem repeats of PREL motifs; PP1, PP1-
binding domains. Taken from37.  
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1.6. Protein/PP1 complex in dendritic spines 
   As aforementioned, PP1 is ubiquitously expressed41. However, in the brain, more 
specifically in neurons, PP1α and PP1γ1 isoforms are highly localized to dendritic spines24. 
PP1 has been identified as a key regulator in both LTP and LTD, with PP1 inhibiting LTP while 
promoting LTD. In fact, LTD-inducing stimuli promotes distribution of PP1 to dendritic 
spines, where it can dephosphorylate its substrates, such as calcium/calmodulin-
dependent protein kinase II (CaMKII), AMPA and NMDA receptors.22 
Neurabin-1 is highly concentrated in dendritic spines, even though it can be found 
in dendrites, axons, terminals and glia.42 Within dendritic spines, Neurabin-1 can be found 
at high levels in the PSD and the 100nm subjacent to it. In fact, Neurabin-1 concentration 
falls with increasing distance from synapse. Neurabin-1 knockout mice exhibited a deficit 
in contextual fear memory and increased AMPA receptor synaptic transmission, suggesting 
that neurabin-1 regulates LTP. Additionally, neurabin-1 overexpression induced filopodia 
and dendritic spines, further suggesting that it has an important role in spine 
morphogenesis30.  
Neurabin-2 is highly enriched at the synaptic membrane in dendritic spines, where 
it regulates the actin cytoskeleton42. Within dendritic spines, neurabin-2 localization is 
similar to that neurabin-1. It is predominantly localized in the PSD and the subjacent 100nm 
of it, with its concentration decreasing with increasing distance from synapse. Knockout 
mice exhibited a marked increase in spine density during development and altered 
filopodia formation, suggesting it functions as a negative regulator of spine 
morphogenesis34.  
Neurabin-1 and neurabin-2 can form hetero- and homodimers and rapidly shuttle 
on and off the actin cytoskeleton34. Through interaction with their respective partners, they 
are able to regulate spine morphology and density, receptor function and synaptic 
plasticity. They bind an overlapping set of targets with some opposing effects42. Also, as 
beforementioned, neurabin-1 overexpression induced filopodia and dendritic spines while 
neurabin-2 knockout mice exhibited a marked increase in spine density during 
development43,44. Additionally, neurabin-1 and neurabin-2 seem to have opposing effects 
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on the regulation of R4-RGS. Due to all these opposing effects, it has been proposed that 
neurabin-1 and neurabin-2 may act as negative regulators of each other, especially in 
dendritic spines, where they are highly concentrated32. 
Both neurabins were initially identified as being PP1-targeting subunits. However, 
between PP1 isoforms, both neurabins showed a significant preference for PP1γ1 and PP1α 
over PP1β. Since neurabins showed enhanced localization to dendritic spines, this 
preference is to be expected, as both PP1 isoforms are enriched in dendritic spines, while 
PP1β is more enriched at the neuronal cell body25. 
Disrupting the neurabins/PP1 complex prevents PP1 from reaching some of its 
targets, thus preventing PP1-mediated dephosphorylation of its substrates. The neurabin-
1/PP1 complex is important in the formation of filopodia in young neurons and the 
transformation of neuronal filopodia into dendritic spines, since it has been shown that 
disrupting of its complex enhances filopodia and impairs surface GluR1 expression, 
hindering the morphological and functional maturation of dendritic spines43. Neurabin-2 
targets PP1 to several substrates in dendritic spines (such as AMPA and NMDA receptors), 
controlling their phosphorylation of the AMPA receptors, decreasing the rundown of AMPA 
currents and increasing the latter’s activity. 
The neurabins/PP1 complex can be disrupted by phosphorylation. It has been 
shown that cAMP-dependent protein kinase catalytic subunit alpha (PKA) phosphorylation 
of neurabin-1 at ser-461 results in the drastic reduction of PP1 activity, allowing neurabin-
1 recruitment of other proteins. Even though the RVxF-flanking serine of neurabin-1 is 
conserved in neurabin-2, PKA does not phosphorylate neurabin-2 at the same site. Instead, 
it phosphorylates a serine residue in the F-actin binding domain (Ser-94)44. This does not 
result in reduced PP1 affinity for neurabin-2, but does reduce neurabin-2 interaction with 
F-actin, displacing neurabin-2 from the PSD to the cytosol, which may ultimately serve to 
control PP1-mediated changes in the actin cytoskeleton or PP1 anchoring to receptors45. 
Neurabin-1 and 2 share a conserve site at Ser-17 for cyclin-dependent-like kinase 5 
(Cdk5) phosphorylation44. However, different research groups reached two different 
conclusions on neurabin-1 phosphorylation by Cdk5. Futter et al, 2005 showed that 
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neurabin-1 can be phosphorylated by Cdk5 at ser-17 in vitro, while Causeret et al 2007 did 
not, reporting Cdk5 phosphorylation at Ser-95 instead. This latter research group found 
that Ser-95 phosphorylation of Neurabin-1 affects its ability to bind to F-actin, thus 
regulating neuronal morphology.30,46 As for Neurabin-2, Cdk5 phosphorylation at Ser-17 did 
not affect its ability to bind to F-actin, while extracellular signal-regulated kinase 2 (ERK2) 
Ser-15 phosphorylation did. This latter kinase can also phosphorylate neurabin-1 at Ser-15, 
at least in vitro. However, the effect of this phosphorylation was not tested44,46.  
Additionally, neurabin-2 can also be phosphorylated by CaMKII (Ser-100 and Ser-
116), which, as with PKA phosphorylation at Ser-94, reduces neurabin-2 ability to bind to 
F-actin47. Neurabin-2 phosphorylated at Ser-100 showed enhanced concentration in 
membrane fractions, including the synaptosomal membrane and synaptic plasma 
membrane. Both CaMKII and PP1 are enriched in the PSD (with the latter being bound to 
neurabin-2 which, in turn, is bound to F-actin)47. 
CaMKII is auto phosphorylated at Thr-286, a critical process for the regulation of 
synaptic signaling, and PP1 selectively dephosphorylates phosphor-Thr-286 CaMKII, 
preventing its association with NMDA and AMPA receptors. So, CaMKII phosphorylation of 
neurabin-2 may reduce the interaction between the neurabin-2/PP1 complex with F-actin, 
thus preventing PP1 from dephosphorylating phospho-Thr-286 CaMKII45. 
Moreover, neurabin-2 localization was shown to vary depending on the kinase that 
phosphorylates it. Thus, it has been suggested that phosphorylation of neurabin-2 
regulates subcellular localization of the neurabin-2/PP1 complex, targeting this complex to 
specific locations within dendritic spines47. Finally, since neurabin-1 can also be 
phosphorylated by PKA, ERK2 and Cdk5, but not CaMKII, it has been suggested that both 
Neurabin-1 and 2 scaffolding functions are differentially regulated by phosphorylation44. 
To summarize, Neurabin-1 and 2 are scaffolding proteins, which can target PP1 (and 
also other proteins) to different location within dendritic spines. They seem to act as 
opposing regulators of each other since they have opposing effects on the actin dynamic 
of dendritic spines and R4-RGS regulation48. Additionally, their localization, and 
consequently PP1 localization, changes; depending on whether they are phosphorylated or 
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not, which may explain how they can target PP1 to specific substrates within different 
cellular compartments.  
Likewise relevant to cytoskeletal dynamics is the report that G-actin and PP1 
competitively bind to the C-terminal region and the formation of the Phactr/PP1 complex 
is inhibited by an increase in the cytoplasmic G-actin concentration, which is induced by 
extracellular signals such as serum. The current hypothesis suggests that the Phactr/PP1 
complex is controlled by the changes in the cytoplasmic G-actin concentration, which 
regulate the actin cytoskeleton dynamics by modulating the phosphorylation status of actin 
regulatory proteins. This suggests that Phactr proteins regulate both the PP1 activity and 
subcellular localization by sensing the cytoplasmic actin concentration through RPEL 
motifs49,50.  
The catalytic subunit of PP1 forms many other complexes, for instance it interacts 
with noncatalytic subunits that determine the activity, substrate specificity, and subcellular 
localization of the phosphatase. PP1 can dephosphorylate cofilin and myosin. The actin 
filament-severing activity of cofilin, which stimulates the treadmill-like movement of the 
actin cytoskeleton in the lamellipodia and filopodia, is controlled by its phosphorylation 
status, and the force-generating activity of myosin is controlled by the phosphorylation 
status of myosin itself. In this context, several studies have shown that the 
Phactr/PP1complex modulates the phosphorylation status of cofilin or myosin, thereby 
regulating actin cytoskeleton dynamics49,50. 
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2. Objectives 
 
Protein phosphorylation is a major regulatory mechanism in cellular processes, 
involving protein kinases and phosphatases. Of particular note, protein phosphatases exert 
their activity via the formation of protein complexes. The main aim of this thesis was to 
review PP1 complexes and to evaluate the effects of Aβ on three proteins implicated in 
dendritic spine morphogenesis and dynamics, Neurabin-1 (PPP1R9A), Neurabin-2 
(PPP1R9B) and Phactr3, as well as their interaction with PP1. 
The specific objectives were to: 
- elucidate the network representing PP1 interactions with Neurabin-1, 
Neurabin-2, Phactr3 and Cofilin 1; 
- study the effect of Aβ on the expression levels of Neurabin-1, Neurabin-2 and 
Phactr3; 
- evaluate the effects of Aβ on the interaction of Neurabin-1, Neurabin-2 and 
Phactr3 with PP1 isoforms, PP1α and PP1γ. 
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3. Materials and methods 
 
3.1. Interactome Networks 
To understand the relationship between different proteins we often resort to a 
systems biology approach to depict the known protein interactions, and these can be 
represented in networks. For this study key proteins were used for developing the 
interactome networks; namely PP1, PP1, Neurabin 1, Neurabin 2, Phactr3 and Cofilin 1. 
The uniprot code for the Homo sapiens of each of the key proteins was retrieved, in 
order to eliminate interactions described in other species, and submitted to IntAct 
Molecular Interaction Database (see Table 1). Different databases (IntAct, String and 
BioGRID) were tested and IntAct demonstrated to be more complete and reliable, as well 
as being a curated source. For the PP1 networks two distinct sources were used. Given the 
expertise in our laboratory several PP1 interactors have been identified using the yeast two 
hybrid (YTH) system. There are over 400 known PP1 interactors19. Hence for the PP1 
analyses the YTH data and the IntAct data were pooled. 
Table 1 - List of Key Proteins retrieved from uniport and submitted to IntAct to obtain interactome network. 
PPP1CA/PP1α; PPP1CC/PP1γ; PPP1R9A/Neurabin-1; PPP1R9B/Neurabin-2; PHACTR3/Phactr3; CFL1, Cofilin. 
Protein Code Uniprot accession number Nº of interacting proteins 
PPP1CA  P62136  298 
PPP1CC  P36873-2  258 
PPP1R9A Q9ULJ8 6 
PPP1R9B Q96SB3 16 
PHACTR3 Q96KR7 8 
CFL1 P23528 24 
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All data recovered from IntAct were transferred to Cytoscape and the interactome 
networks were built for each protein and merged, so as to identify key proteins as 
presented in the results. The output from the databases is as the gene name, but given that 
were are dealing with protein:protein interactions, the term protein will be used. 
 
3.2. Antibodies 
Antibodies can be classified as monoclonal or polyclonal. Monoclonal antibodies 
contain a single antibody clone from B-Cells and recognize a single epitope from the 
antigen, while polyclonal antibodies contain several clones of antibodies recognizing 
different epitopes in the antigen. Monoclonal antibodies are highly specific, but less 
sensitive, while polyclonal antibodies are highly sensitive, but less specific.  
Antibodies are central to the procedures carried out in the work here presented. 
The antibodies were used for Western blot analysis and immunoprecipitation procedures 
as indicated in table 2.  Anti-PP1α and anti-PP1β were produced ‘in house’. The remaining 
antibodies, primary and secondary, were obtained from commercial sources.  
The following tables (Table 2 and Table 3) summarize the antibodies used in this 
work.  
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Table 2- Primary antibodies and dilutions used. 
Antibody Type Target Dilution 
Anti-Neurabin I (D-4 Santa 
Cruz Biotechnology, Inc.) 
Mouse, polyclonal Neurabin 1 WB: 1:1000 
Anti-PPP1R9B 
(Proteintech) 
Rabbit, polyclonal Neurabin 2 WB: 1:1000 
Anti-Phactr3 (Proteintech) Rabbit, polyclonal Phactr3 WB: 1:1000 
Anti-PP1α (CBC2C)51 Rabbit, polyclonal PP1α 
WB: 1:5000 
Co-IP: 4µL/1000µg 
Anti-PP1γ (CBC3C)51 Rabbit, polyclonal PP1β 
WB: 1:5000 
Co-IP: 3µL/1000µg 
 
Table 3- Secondary antibodies used. 
Antibody Target Dilution 
Horseradish peroxidase-conjugated anti-
mouse (Amershan Pharmacia) 
Anti-mouse primary antibodies 1:5000 
Horseradish peroxidase-conjugated anti-
rabbit (Amershan Pharmacia 
Anti-rabbit primary antibodies 1:5000 
 
3.3. Culture, growth and maintenance of SH-SY5Y cell 
line 
In neurosciences the use of mammalian neurons derived from embryonic the CNS 
tissue is very limited mainly because once these cells are terminally differentiated into 
mature neurons, they can no longer be propagated. 
To overcome this limitation transformed neuron-like cell lines are commonly used. 
Among them, there is a very popular and well characterized cell line, the SH-SY5Y 
neuroblastoma cell line (ATCC® CRL-2266™).52 
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The SH-SY5Y cell line was originally derived from a metastatic bone tumor biopsy, 
and a subline of the parental line SK-N-SH, which were subcloned three times: first to SH-
SY, them to SH-SY5, and finally to SH-SY5Y.52 
In order to achieve the objectives proposed for the present study, the SH-SY5Y 
neuroblastoma cell line was chosen for the reasons described above, and because this cell 
line is a human cell line that can be easily differentiated into a more mature neuronal-like 
phenotype.  
SH-SY5Y cells (ATCC CRL-2266) were grown and maintained in Minimal Essential 
Medium (MEM)/F12 (1:1) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS), 0,5 mM L-Glutamine, 100 U/ml streptomycin. Cultures were maintained at 37ºC, 5% 
CO2. Cells were subcultured when 80-90% confluence was reached. 
3.3.1. Differentiation of the SH-SY5Y neuroblastoma cell 
line   
SH-SY5Y cells can be differentiated into a neuronal-like phenotype through 
treatment with several compounds. Retinoic acid (RA), is one of the most commonly used 
compounds. It is a vitamin A derivative, with growth inhibiting and differentiation-
promoting properties. Several variations of differentiation medium can be found in the 
literature, however it is usually administered at 10µM in free-serum or low serum medium.  
SH-SY5Y underwent differentiation in 1%FBS Serum, with 10µM RA for 7 days, 
with medium renewal every 2 days. To confirm differentiation cells were cultured in the 
same medium without RA. 
3.4. Aβ treatment 
In order to evaluate the effects of Aβ on the expression and interaction of Neurabin 
1, Neurabin 2 and Phactr3, with PP1α and PP1γ, SH-SY5Y cell line were incubated with 
different concentrations of Aβ peptide. 
Synthetic Aβ 1-42 (GenicBio) was dissolved in water in order to prepare 1mM stock 
solution. Prior to cell exposure, an aggregation step was performed, by incubating the 
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peptides with phosphate buffered saline (PBS) 1x, 48h at 37ºC to a final concentration of 
100µM. 
SH-SY5Y cells were incubated for 7 days as described in Section 3.1.1. and then 
incubated in serum free MEM/F12 1:1 medium, supplemented with 0.5mM L-Glutamine, 
100U/mL penicillin, 100U/mL Streptomycin and 10µM RA with 2µM and 10µM of Aβ 1-42. 
Prior to treatment cell were washed twice with PBS 1X. 
In order to assure that the results obtained were not due to PBS1x, used to 
aggregate Aβ peptide, control cultures were incubated with PBS1x vehicle. 
 
3.5. Lysates and protein quantification 
Depending on the experimental procedure, cells were collected using different 
methods. 
To analyze protein expression, cells were collected with 200µL of RIPA buffer. RIPA 
buffer, contains sodium dodecyl sulfate (SDS), which is a strong ionic detergent. It is able 
to solubilize lipids and proteins contained in cell membrane, creating pores leading to full 
cell lysis. The lysates were subjected to western blot analysis. 
To analyze protein interactions through co-immunoprecipitation (Co-IP), cells were 
collected using lysis buffer (50mM Tris-HCL pH8.0, 120mM NaCl, 4%CHAPS) containing 
protease inhibitors (cOmpleteTM EDTA-free, Roche), to prevent proteolysis, 
dephophorylation and denaturation of proteins. The lysis buffer was freshly prepared.  
 
Following protein extraction, protein concentrations were measured through 
Pierce’s bicinchoninic acid (BCA) protein assay kit (Thermo Scientific) following the 
manufacturer’s instructions. In an alkaline medium, proteins reduce Cu2+ to Cu1+, which 
links to bicinchoninic acid allowing a highly sensitive and selective colorimetric detection. 
96-well Plates were used to perform BCA assay. Standard samples were prepared with 
known concentrations of bovine serum albumin (BSA)(see Table 3). Cell samples were 
prepared by mixing 5ul of lysate with 20uL of SDS1%, and incubated with 200µl working 
reagent. The working reagent was prepared by mixing BCA reagent A and B in 50:1 
proportion. The 96well plate was incubated 30min, at 37ºC. After cooling to room 
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temperature, absorbance was measured at 562nm using a microplate reader (Infinite 
M200, TECAN). To determine protein concentration, a standard curve was calculated by 
plotting standard absorbance vs standard BSA concentration.  
All measurements were performed in duplicate. 
 
 
 
Table 4 - Protein standards used in BCA assay. 
Standard BSA (µL) SDS1%(µL) Protein Mass (µg) 
P0 0 25 0 
P1 1 24 2 
P2 2 23 4 
P3 5 20 10 
P4 10 15 20 
P5 20 5 40 
 
3.6. Co-Immunoprecipitation  
To evaluate Aβ influence on PP1 complexes (both α and γ isoforms) with Neurabin 
1, Neurabin 2 and Phactr3, a co-immunoprecipitation (Co-IP) was performed using lysates 
of SH-SY5Y cells. The Co-IP is a variation of immunoprecipitation, which relies in the 
immunodepletion of a protein of interest (PP1 isoforms), together with all interacting 
proteins (i.e. Neurabin 1, Neurabin 2 and Phactr3) in solution. 
 
The Co-IP assay was performed using Dynabeads Protein G (Invitrogen), due to 
rapid and easy magnetic bead separation. This method preserves most of protein-protein 
interactions, and reduces background caused by non-specific binding. The procedure is 
based in the capacity of Dynabeads protein G binding to the Fc region of antibodies. The 
antibody-bound beads are placed in a Dynal magnet, which allows the beads to migrate to 
the magnet side, allowing easy supernatant removal. Sample proteins are loaded onto the 
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beads, permitting the binding of protein of interest and all interacting proteins 
consequently. By placing the complex in the Dynal magnet, and removing the supernatant, 
only the protein complex of interest remains. In this experimental procedure, the complex 
was analyzed through SDS-PAGE.  
 
Cell cultures were performed as described in Section 3.1.1., at a 1x10^5 cell density. 
Following Aβ treatment for 24h, cells were washed with cold PBS1x and gently scrapped 
off the culture plate with Lysis buffer described in Section 3.5. Lysates were sonicated twice 
for 10seconds.  
 
Each sample had its mass normalized by BCA assay and 1000ug of each sample were 
precleared using 15µl of Dynabeads for 1h, 4ºC with agitation. Simultaneously, the primary 
antibody (PP1α and γ as depicted in Table 2) was incubated with 40µL of Dynabeads in the 
same conditions. Prior to use, Dynabeads were washed thrice with washing solution 
(3%BSA/PBS1x). 
 
After 1h, each sample was transferred to the antibody-bound beads, and incubated 
overnight, 4ºC with agitation. Following incubation, supernatant was removed, and the 
beads washed thrice with 500µL of PBS1x, 10min at 4ºC with agitation. After the last wash, 
supernatant was fully discarded and 100µL of Loading Buffer (LB) was added to the beads, 
boiled for 10min at 90ºC to disrupt beads-proteins complex. Dynabeads were removed and 
samples stored at -20ºC until needed. 
Co-IP controls were performed by incubated cell lysates with either Dynabeads 
without antibody, or Dynabeads with IgG controls.  
 
 
 
 
34 
 
3.7. Western Blot 
Western Blot or Immunoblot, is a widely used technique for detection and analysis 
of proteins. It comprises several steps. Initially prepared samples are separated by 
electrophoresis and lastly transferred to a nitrocellulose membrane. The membranes are 
incubated with antibodies to allow detection and further analysis.  
In this experimental procedure, electrophoresis gels in 5-20% gradient SDS-PAGE 
were used, allowing protein separation only by molecular weight. It consists of 2 two gels, 
a resolving gel (bottom), with higher polyacrylamide concentration to separate proteins, 
and a stacking gel (top) with a lower polyacrylamide concentration.  
Prior to loading, the samples are incubated with Loading Buffer (LB). The loading 
buffer consists of glycerol, to increase sample density, SDS, to mask any inherent charge of 
proteins, β-mercaptoethanol (reducing agent), breaking disulfide bonds and thus 
disrupting quaternary and tertiary structures, and bromophenol blue (dye), which allows 
sample tracking and progression in the gel. 
Electrical current is applied, enabling protein separation. After separation, proteins 
are transferred by electrophoresis onto a nitro-cellulose membrane. This immobilizes all 
proteins at their relatively migration positions.  
The membranes can be stained with Ponceau S, to confirm protein transfer and 
assess equal gel loading. Membranes are then blocked with either non-fat milk or BSA, in 
order to block non-specific sites of the primary anti-body. Following blocking, membranes 
are incubated with specific primary antibody and appropriate secondary antibody. After 
antibody biding, proteins can be detected by chemiluminescence. The horseradish 
peroxidase conjugated onto secondary antibody, catalyze the oxidation of luminol, 
emitting light. This light signal can be detected with appropriated equipment, Chemidoc 
XR, BioRad, and the resulting images further analyzed with Image Lab, BioRad.  
In the present work, samples were collected, and protein concentration determined 
as described in Section 3.5. The samples were separated in a 5-20% gradient SDS-PAGE in 
a Hoefer electrophoresis system. The gradient gels were prepared and allowed to 
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polymerize for at least 45minutes at room temperature. The stacking gels were prepared 
and polymerized on the top of the gradient gel. A comb was inserted before polymerization 
of the stacking gel, and removed only after polymerization was ensured. The samples were 
incubated with 4X LB for 10min at 90ºC.  
Samples were loaded onto the gel alongside a molecular weight marker (Precision 
Plus Protein Dual Color Standards, BioRad). The gels were run at 90mA for approximately 
3hours. Proteins were then transferred onto nitro-cellulose membranes for 18hours at 
200mA.  
Membranes were incubated with Ponceau S for 5 minutes and photographed in 
Chemidoc (BioRad) to ensure equal gel loading. Following washing TBS-T1x to remove 
Ponceau S, membranes were blocked with 5% BSA in Tris Buffered Saline Tween (TBS-T) 1x 
for 4hours. Membranes were then washed in TBS-T 1x, 10min, and incubated with a specific 
primary antibody overnight (Anti-Neurabin-1, Anti-PPP1R9B, Anti-PHACTR3) or for 2 hours 
at room temperature (Anti-PP1α and Anti-PP1γ), washed thrice with TBS-T1x, 10min, 
incubated with appropriated secondary antibody for 2hours and washed thrice with TBS-
T1x, 10min. Following washing, membranes were incubated with enhanced luminescence 
(ECL) detection kit for 1minute. After incubation with ECL membranes were exposed in 
Chemidoc XR, BioRad. Band intensity was determined and used to correlate with 
intracellular protein levels.  
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4. Results and discussion 
4.1. PP1 Interactome 
In order to select potential candidates to study the effects of Aβ in Protein/PP1 
complexes, the interactome of PP1 was identified using a systems approach. Firstly, 
PP1α and PP1γ interactors were retrieved from IntAct, as well additional PP1 
interactors identified previously by our laboratory by yeast to hybrid (YTH) system, but 
not present in the database (Figure 7)19. Analysis of the merged network of the two 
isoforms reveals that each central node has a significant number of interactors (as 
indicated in table 1), but there is also a significant number of overlapping nodes. In fact, 
82 interactors are shared by PP1α and PP1γ. 
Upon analyzing the GeneOntology (GO) of the PP1 merged interactome the 
most represented Molecular Functions (MF) were protein binding/binding, Catalytic 
activity, Kinases and phosphatase activity (supplemental figure 1). It is also worth noting 
that cytoskeletal protein binding and actin binding are also well represented as well as 
receptor binding activity. Taken together the major nodes in the MF point to important 
roles for PP1 as important signal transduction mediators, this is highly consistent with 
all the available information on PP1. 
 
 
 
 
 
 
 
 
 
 
 
 
40 
 
 
 
 
Upon analyzing the PP1 merged interactomes (Figure 7), proteins implicated in 
synapse plasticity and neuronal morphology were also present and these were selected 
for further analysis. The candidate proteins were Neurabin-1, Neurabin-2, Cofilin 1 and 
Phactr3.  All these interact directly with PP1 and all have important roles in synapse 
plasticity and morphology. Consequently, the interacting proteins for each were 
retrieved from IntAct. The interactomes of the above mentioned proteins were merged 
with those of PP1α and PP1γ and are shown in figure 8. It was very striking that the 
Figure 7- Interactome network, of PP1α and PP1γ. PPP1CA, PP1α; PPP1CC, PP1γ; Highlighted border for key proteins; 
Pink, Phactr3; Blue, Neurabin-1, Yellow, Neurabin-2.  
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merged interactome of these 6 central nodes had only an additional 10 interactors 
when compared to the merged interactome of PP1α and PP1γ alone. This represents a 
strong overlap of interactors and is suggestive of very close functional relationships. 
Also of note PP1α and PP1γ remain as central nodes (Figure 8). It is also noteworthy 
that a central hub emerged around Cofilin 1 (CFL1). In the experimental design CF1 was 
not highlighted for subsequent studies, but given the data emerging from this systems 
approach it will have to be included in follow up analysis. 
 
Figure 8 – Merged Interactome Network of PP1α, PP1γ, Neurabin-1, Neurabin-2, Phactr3 and Cofilin.  
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The GO for MF of the 6 merged interactome networks was also investigated 
(supplemental figure 2). Not surprisingly the most represented MFs remained the same 
when compared to the merged PP1 network, that is: catalytic activity, Kinases and 
phosphatase activity, cytoskeletal protein binding and actin binding. This is so because the 
total number of nodes for the two merged networks is almost the same. (see if there are 
any differences) 
Subsequently only proteins which interact with PP1 isoforms and another interactor were 
selected (Figure 9). This was important to simplify the network and home in on key nodes. 
By doing so we obtained a list of candidate proteins that interact with PP1. Given the 
central role of PP1 in AD and the fact that Aβ is a model to study AD in cell cultures 14,53,54, 
Figure 9 - Interactome Network of proteins directly binding to PP1α and PP1γ. Colored nodes represent most relevant 
proteins. PPP1CA, PP1α; PPP11CC, PP1γ; PPP1R9A, Neurabin – 1; PPP1R9B, Neurabin – 2; PHACTR3, Phactr3; CFL1, Cofilin. 
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the nodes identified in Figure 9 are potential targets to study the effect of Aβ at a molecular 
level. 
The final sub-network of common interactors yielded a total of 103 nodes (Figure 
9). It is noteworthy that this came from an original pool of around 500 proteins. Thus one 
can deduce that this was important to simplify the network and home in on key nodes for 
future studies. Emerging central nodes from this work that deserve to be further addressed 
in future studies include MYO 19, GRB2, CAPZA2, MYO1C, SYNPO and PHACTR4. These are 
important because they have several interactors and can potentially be central hubs. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
4.2. Differentiation of the SH-SY5Y cell line 
In order to use a cell line closer to characteristics of a neuron, SH-SY5Y cell line, was 
differentiated for 7days, with media renewal every 2 days. Photographs were taken every 
two days to access correct differentiation. 
To evaluate cell differentiation morphological changes were analyzed, such as 
neurite extension. Non-differentiated cells, were used as a control to access morphological 
changes. 
 
4.2.1. Morphology evaluation  
To evaluate the morphological changes induced by differentiation media, 
photographs were taken prior to media change, every 2 days, as depicted in the following 
images (Figure 10).  
It was possible to observe that cells in media with 10% FBS and 1%FBS, the 
proliferative rate was higher than media with retinoic acid. However cells in 1%FBS media, 
show some neurite extention compared to cells in 10% FBS media. This can be explained 
by depletion of serum, essential for cell proliferation, which may induce some cells to 
differentiate. Cells in differentiation media (1% FBS and 10uM RA) show higher neurite 
extention, as expected. With this data it is possible to access a proper differentiation of SH-
SY5Y cell line, and conclude that the characteristics of the cells were as close as possible to 
a neuronal cell, and the requirements to study Protein/PP1 complexes were met.  
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Figure 10- Phase contrast photographs of SH-SY5Y cell line morphology during differentiation. White 
arrows represent extended neurites. White triangles represent “S” population. 
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4.3. Aβ effect on Neurabin expression 
Aβ is a neurotoxic peptide, which is reported to cause spine and synapse 
degeneration. Even when applied extracellularly it causes neurite damage, leading to spine 
degeneration. Several studies, including from our own laboratory, have been carried out 
using cell exposure to Aβ as an AD model system55,56. 
As discussed in the introduction synaptic dysfunction is an AD hallmark. Further, 
since neurabins are concentrated in the spine it is possible that in the presence of Aβ, their 
expression could be decreased.  
In order to evaluate this hypothesis, differentiated SH-SY5Y cells were treated with 
two different concentrations of the toxic peptide (previously aggregated), 2µM and 10µM. 
The sample lysates of the cells collected were analyzed by western blot in order to evaluate 
changes in intracellular protein levels (Figure 11).  
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The results obtained, show a significant decrease in intracellular Neurabin levels. It  
is observed for both neurabins, and may be due dendritic spine degeneration caused by 
Aβ. This suggest that in AD, the decrease in this protein may lead do dysregulation of the 
actin dynamics, leading to dendritic spine a synapse loss. Whether this is the synaptic loss 
so well described for AD remains to be directly demonstrated, but it is nonetheless a very 
attractive hypothesis. 
 
 
 
 
 
A 
120kD 
200kD 
180kD 
 
B 
C 
Neurabin-2 
Control Aβ 2µM Aβ 10µM 
Neurabin-1 
D
D 
Figure 11 - Neurabin-1 and Neurabin-2 expression in SH-SY5Y cells treated with Aβ1-42. A. Western blot analysis of 
SH-SY5Y lysates treated with different concentrations of Aβ1-42. B. Loading Control, Ponceau Staining. C. Comparison 
of Neurabin-2 expression levels in cells for different concentrations of Aβ1-42. D. Comparison of Neurabin-2 
expression levels in cells for different concentrations of Aβ1-42. All data was normalized to Ponceau S levels prior to 
analysis. * P < 0,05; n.s, no significant difference, P>0,05. 
* * 
* * 
n.s 
n.s 
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4.4. Aβ effect on Phactr3 expression 
 
As already discussed, Aβ is a neurotoxic peptide. It was reported that Aβ interferes 
with cytoskeleton dynamics, thus interfering with actin levels and interfering with 
polymerization/depolymerization of F-actin, increasing its polymerization57. It is also 
known that Phactr3 is regulated by the levels of G-actin and regulates several proteins 
involved in cytoskeleton and actin dynamics. This leads to an indirect effect of Aβ on 
Phactr3 expression37.  
 
 
 
Figure 12- Phactr3 expression in SH-SY5Y cells treated with Aβ1-42. A. western Blot analysis of SH-SY5Y lysates treated 
with different concentrations of Aβ1-42. B. Loading Control, Ponceau Staining C. Comparison of Phactr3 expression levels 
in cells for different concentrations of Aβ1-42. All data was normalized to Ponceau S levels prior to analysis. n.s, no 
significant difference, P>0,05. 
75kD 
Phactr3 
Control Aβ 2µM A Aβ 10µM 
B 
C n.s 
n.s 
n.s 
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The results obtained (Figure 12), show an increase in intracellular protein levels for 
Phactr3 following Aβ treatment at 10µM concentration. This may be due to a deregulation 
in the actin levels induced by Aβ, leading to an increase in Phactr3 expression levels. This 
will have to be further tested.  However, Phactr3 is also known to regulate actin-monomer-
sequestering proteins, such as cofilin, which leads to depolymerization of actin. With these 
results one can hypothesize, that the increase in F-actin polymerization leads Phactr3 to 
regulate proteins capable of depolymerizing actin to recover Aβ induced anomalies.  
 
 
4.5. Aβ effect on Protein/PP1 complexes  
 
All three proteins above tested can interact with PP1 to regulate several aspects in 
neuronal morphology and synapse plasticity. Since cells treated with Aβ undergo 
morphological and synapse changes, the interference of Aβ with Proteins/PP1 complexes 
as a mode of action was tested. In order to do so, a co-Immunoprecipitations were 
performed, using PP1α and PP1γ antibodies to precipitate both isoforms of PP1 and all 
coupled proteins (Figures 13 and 14).  
The results obtained show a decrease with increasing Aβ concentration in the 
interaction of Neurabin-1 and PP1. Like the whole lysates tested previously we can see a 
decrease in the intracellular level of Neurabin-1.  However not only in the 
Immunoprecipitations lysates we can see the same decrease in bands intensity, one of the 
two bands of Neurabin-1 failed to appear in cells treated with Aβ. However due to 
experimental problems it was impossible to obtain results for the Control band in the co-
immunoprecipitation performed with anti-PP1α (Figure 13). Despite this setback, it is still 
possible to verify a decrease from cells treated with 2µM of Aβ to cells treated with 10µM. 
This suggests that Aβ has an effect in the Neurabin-1/PP1α complex, however to better 
conclude, these preliminary results should be replicated. The same was observed for 
Phactr3/PP1α. However, no difference was observed with Neurabin-2. 
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Figure 13- Co-immunoprecipitation of PP1α binding proteins in SH-SY5Y. Western blot was performed using anti-PP1α to ensure 
that PP1α was immunoprecipitated, and anti-Neurabin-1, anti-Neurabin-2, and anti-Phactr3 antibodies to test interaction with 
PP1α. C, controls; 2µM and 10µM, treatment with Aβ1-42 at 2µM and 10µM concentration respectively; IgG, Immunoglobulin G 
control; Negative, Dynabeads control performed without anti-PP1α. 
Figure 14 - Co-immunoprecipitation of PP1γ binding proteins in SH-SY5Y. Western blot was performed using anti-PP1γ to ensure 
that PP1γ was immunoprecipitated, and anti-Neurabin-1, anti-Neurabin-2, and anti-Phactr3 antibodies to test interaction with 
PP1γ. C, controls; 2µM and 10µM, treatment with Aβ1-42 at 2µM and 10µM concentration respectively; IgG, Immunoglobulin G 
control; Negative, Dynabeads control performed without anti-PP1γ. 
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Similarly, to PP1α, the co-immunoprecipitation performed with PP1γ, yields 
similarly results.  For Neurabin-1/PP1γ complex, a decrease in intracellular protein levels 
can be observed, however as not as prominent as with PP1α.  
Phactr3, also showed a decrease in interaction with PP1 (Figures 13 and 14). As 
mentioned previously Aβ interferes with actin dynamics, and the levels of Phactr3 are 
dictated by actin levels, which could lead to an increase in expression of Phactr3 in response 
to the effects of Aβ. It is known that Phactr3 regulates other proteins, to depolymerize 
excess F-actin. By interacting with other proteins, the affinity towards PP1 may be lower, 
and thus a decrease in interaction.  
In Neurabin-2 no differences were observed regarding interaction with both 
isoforms of PP1.   
It is also known that in cells treated with Aβ, PP1 expression and activity is 
decreased58. Thus, the decrease in interaction between both proteins could be a result of 
a decrease in expression levels and or loss of activity.  
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5. Conclusion 
The integration of network interactome and gene oncology allowed for a study of 
PP1 interactors as well their molecular functions. Potential candidates to study the effects 
of Aβ in Protein/PP1 complexes were identified using a systems approach. Interactors 
retrieved from IntAct, as well additional PP1 interactors identified previously by our 
laboratory by yeast to hybrid (YTH) system. Analysis of the merged network of the two 
isoforms reveals that each central node has a significant number of interactors (>200), as 
well 82 interactors are shared by PP1α and PP1γ. 
The GeneOntology analysis of the PP1 merged interactome revealed that the most 
represented Molecular Functions were protein binding/binding, Catalytic activity, Kinases 
and phosphatase activity. Cytoskeletal protein binding and actin binding are also well 
represented as well as receptor binding activity. This major nodes in the Molecular 
Functions point to important roles for PP1 as important signal transduction mediators. By 
merging PP1 interactomes, proteins implicated in synapse plasticity and neuronal 
morphology were identified and selected for further analysis (Neurabin-1, Neurabin-2, 
Phactr3 and Cofilin1). The interactomes of these central nodes were merged with those of 
PP1α and PP1γ, and revealed only additional 10 interactors when compared with the PP1 
isoforms interactome, revealing a very close functional relationship. Even though a central 
hub emerged around Cofilin 1, subsequent studies were not pursued.  
To home in key nodes for future studies, it was very important to simplify the 
network. From an initial pool of 474 proteins, the final sub-network of common interactors 
yielded a total of 103 nodes.  
This thesis was aimed at evaluating whether Aβ could affect Neurabin-1, Neurabin-
2 and Phactr3 expression, and disrupt the Proteins/PP1 complexes, which are important 
for regulation of synaptic transmission, plasticity and maintenance of dendritic spines’ 
morphology. These are functions that are known to be altered in Alzheimer’s disease 
patients, thus, studying the possible molecular targets of Aβ could help us to have a better 
understanding of neurodegenerative alterations.  
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The results with differentiated SH-SY5Y cells showed a slight decrease in expression 
levels of Neurabin-1 and Neurabin-2, and an increase in expression level of Phactr3, when 
treated with Aβ 1-42. Thus, suggesting that Neurabin expression is decreased, by either, 
loss of synapses and dendrites, or due to neuronal death. If these changes are a result of 
Aβ effects on Neurabins or the neuronal death caused by Aβ it is still unclear.  
The Co-IP results showed a decrease in the interaction between Neurabin-1, 
Phactr3 and PP1, caused by the addition of Aβ to the culture medium. Neurabin-2 
interaction levels with PP1 do not seem to be affected by the addition of Aβ at either 
concentration used. Based on this data, it is possible to hypothesize three different ways 
leading to the disruption of Neurabin-1/PP1 and two different ways leading to the 
disruption of Phactr3/PP1 complex.  
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Figure 16 - Proposed models for the effect of Aβ on the Neurabin/PP1 complex. The Aβ effects on the Neurabin/PP1 complex 
would lead to changes in the spine dynamics, leading to synapse loss and neuronal death. A. Neurabin/PP1 complex under 
normal physiological conditions with PP1 bound to PP1-binding domain. B. Aβ could induce conformational changes in 
Neurabin which would render PP1-binding domain inaccessible. C. Aβ could increase Neurabins affinity towards other proteins 
(binding to the PDZ binding domain, for example) displacing PP1 from PP1-binding domain. D. Aβ could increase the activity of 
a protein kinase, which would phosphorylate Neurabin, displacing PP1. 
PK 
-Decrease in PP1-mediated dephosphorylation of its targets 
-Dysregulation of AMPA and NMDA receptors activity 
-Decrease in maturation and maintenance of dendritic spines 
-Spine retraction and loss of synapses 
-Neuronal death  
Neurabin 
PP1-Binding Domain 
Protein Phosphatase 1 
Protein Kinase 
Protein x 
Phosphate 
Aβ 
A 
D C B 
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Either, the Aβ effect on Neurabin-1: 
i - causes a conformational change, preventing binding to PP1, via the PP1 binding 
motif being inaccessible; 
ii - the Aβ may increase affinity of Neurabin-1 towards another protein, other than 
PP1, competing for the same domain, PDZ or by either displacing PP1 form its binding 
domain; 
iii - and lastly, Aβ could increase activity of a protein kinase, phosphorylating 
Neurabin-1, and consequently, displacing PP1 from it binding site.  
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Figure 17 - Proposed models for the effect of Aβ on the Phactr3/PP1 complex. The Aβ effects on the Phactr3/PP1 complex would lead to 
changes in the spine dynamics, leading to synapse loss and neuronal death. A. Phactr3/PP1 complex under normal physiological conditions 
with PP1 bound to PP1-binding domain. B. Aβ could increase Phactr3 affinity towards G-Actin (binding to the RPEL Motif) displacing PP1 
from PP1-binding domain. C. Aβ could increase Phactr3 affinity towards Cofilin (binding to the RPEL Motif) displacing PP1 from PP1-binding 
domain. 
-Decrease in PP1-mediated dephosphorylation of its targets 
-Decrease in maturation and maintenance of dendritic spines 
-Spine retraction and loss of synapses 
-Neuronal death  
A 
C B 
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Either, the Aβ effect on Phactr3: 
i - the Aβ may increase affinity of Phactr3 towards G-Actin, binding to the RPEL Motif 
and displacing PP1 from PP1-binding domain; 
ii - the Aβ may increase affinity of Phactr3 towards Cofilin; 
These of course are hypotheses which all need to be tested in the future.  
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6. Future perspectives 
 
In the future, it would be important to further study both bands corresponding to 
Neurabin-1 found in the Western Blot analysis. This could elucidate and help us better 
understand the co-immunoprecipitation results and shed light on how Aβ may affect the 
interaction between Neurabin-1 and PP1. To do so, we could cut the SDS-PAGE where the 
respective bands appear, and submit them to mass-spectrometry analysis in order to 
identify the sequence of both isoforms. 
The co-immunoprecipitation assay with SH-SY5Y cells, should be replicated, to 
validate the preliminary results presented in this thesis.  
Additionally, experiments with primary cell cultures could be carried to increase the 
reliability of these results obtained for Neurabin-1, Neurabin-2 and Phactr-3 intracellular 
protein levels in SH-SY5Y cells, upon addition of Aβ. Also given the interactome data, cofilin 
is a central protein and should also be addressed. Other proteins such as MYO 19, GRB2, 
CAPZA2, MYO1C, SYNPO and PHACTR4 could be addressed based in the interactome data 
analysis. 
Finally, an immunocytochemistry assay and determination of co-localization to 
evaluate if the addition of Aβ disrupts Protein/PP1 complexes in vivo, could be performed. 
Alternatively, higher resolution microscopic techniques could be used, such as, 
fluorescence resonance energy transfer (FRET)59 or electron microscopy. 
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7. Appendix 
I. Cell Culture Reagents and Equipment 
Equipment 
 
• Hera cell CO2 incubator (Heraeus) 
• Safety cabinet Hera safe (Heraeus) 
• Inverted optical microscope (LEICA) 
• Hemacytometer (Sigma) 
• Sonicator (U200S (IKA)) 
• Bath SBB6 (Grant) 
 
Solutions 
 
• SH-SY5Y Complete Medium (Eagle’s Minimum Essential Medium/F12 Medium 
1:1) 
For a final volume of 500 ml: 
- 2.4 g MEM 
- 2.655 g F12 
- 0.025 g Sodium Phosphate  
- 0.85 g Sodium Bicarbonate (Sigma) 
- 1.25 mL L-Glutamine (200 mM) 
- 5 mL AA (1%) 
Adjust to pH 7.2-7.4 
- 50 mL FBS (10%) 
Sterilize by filtering through a 0.2 μm filter and store at 4oC.  
 
• PBS (1x)  
For a final volume of 500 ml, dissolve one pack of BupH Modified Dulbecco’s Phosphate 
Buffered Saline Pack (Pierce) in deionised H2O. Final composition:  
- 8 mM Sodium Phosphate  
- 2 mM Potassium Phosphate  
- 140 mM Sodium Chloride  
- 10 mM Potassim Chloride  
Sterilize by filtering through a 0.2 μm filter and store at 4oC.  
 
• Trypsin-EDTA 0,05% (Thermo) 
 
• Trypan Blue solution cell culture tested (Sigma) 
 
• RIPA buffer  
72 
 
To 980 μL of RIPA buffer (Sigma-Aldrich) add:  
- 20 μL Protease inhibitor cocktail (Roche)  
 
• Beta-Amyloid 1-42, TFA (GenicBio) 
 
II. Protein Content Determination 
Equipment 
• Tecan 5000 
Reagents 
• BCA assay kit (Pierce, Rockfort, IL) 
• Bovine Serum Albumin (BSA) (Pierce)  
• Working Reagent (WB) (50 Reagent A : 1 Reagent B) 
o Reagent A: sodium carbonate, sodium bicarbonate, BCA and sodium 
tartrate in 0,2N sodium hydroxide 
o Reagent B: 4% cupric sulfate 
 
III. SDS-PAGE  
 
Equipment 
• Electrophoresis system (Hoefer SE600 vertical unit) 
• Electrophoresis power supply EPS 1000 (Amersham Pharmacia Biotec) 
 
Reagents 
 
• Acrylamide: Bis-Acrylamide 29:1 solution 40%, Dnase, Rnase free (Fisher) 
 
• 10% APS (ammonium persulfate)  
In 10 ml of deionised H2O dissolve 1 g of APS. Note: prepare fresh before use.  
 
• 10% SDS (sodium dodecilsulfate)  
In 10 ml of deionised H2O dissolve 1 g of SDS.  
 
• LGB (Lower gel buffer) (4x)  
To 900 ml of deionised H2O add:  
- 181.65 g Tris  
- 4 g SDS  
Mix until the solutes have dissolved. Adjust the pH to 8.9 and adjust the volume to 1L 
with deionised H2O.  
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• UGB (Upper gel buffer) (5x)  
To 900 ml of deionised H2O add:  
- 75.69 g Tris  
Mix until the solute has dissolved. Adjust the pH to 6.8 and adjust the volume to 1 L with 
deionised H2O.  
 
• Loading Gel Buffer (4x)  
- 2.5 mL 1 M Tris solution (pH 6.8) (250 mM)  
- 0.8 g SDS (8%)  
- 4 ml Glicerol (40%)  
- 2 ml Beta-Mercaptoetanol (2%)  
- 1 mg Bromofenol blue (0.01%)  
Adjust the volume to 10 ml with deionised H2O. Store in darkness at room temperature.  
 
• 1 M Tris (pH 6.8)  
To 150 ml of deionised H2O add:  
- 30.3 g Tris base  
Adjust the pH to 6.8 and adjust the final volume to 250 ml.  
 
• 10x Running Buffer  
- 30.3 g Tris (250 mM)  
- 144.2 g Glycine (2.5 M)  
- 10 g SDS (1%)  
Dissolve in deionised H2O, adjust the pH to 8.3 and adjust the volume to 1 L.  
 
• Stacking (upper)  and Resolving (lower) gel solution   
 Stacking Gel Resolving Gel 
 3.5% 5% 20% 
- H2O 13.83 ml 18.59 ml 7.34 ml 
- 29:1 Bis-Acrylamide 1.75 ml 3.75 ml 15 ml 
- LGB (4x) - 7.5 ml 7.5 ml 
- UGB (5x) 4.0 ml - - 
- 10% APS 200 μL 150 μL 150 μL 
- 10% SDS 200 μL - - 
- TEMED 20 μL 15 μL 15 μL 
 20 mL 60 mL 
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IV. Western-Blotting Solutions and Equipment  
Equipment 
• Transphor Electrophoresis unit (Hofer TE 42) 
• Electrophoresis power supply EPS 1000 (Amersham Pharmacie Biotec) 
 
Reagents 
 
• 1x Transfer Buffer  
- 3.03 g Tris (25 mM)  
- 14.41 g Glycine (192 mM)  
Mix until solutes dissolution. Adjust the pH to 8.3 with HCl and adjust the volume to 800 
ml with deionised H2O. Just prior to use add 200 ml of methanol (20%).  
 
V. ImmunoBlotting Solutions  
 
Equipment 
• ChemiDoc Touch Imaging System (BioRad) 
 
Reagents 
• 10x TBS (Tris buffered saline)  
- 12.11 g Tris (10 mM)  
- 87.66 g NaCl (150 mM)  
Adjust the pH to 8.0 with HCl and adjust the volume to 1L with deionised H2O.  
 
• 10x TBS-T (TBS+Tween)  
- 12.11 g Tris (10 mM)  
- 87.66 g NaCl (150 mM)  
- 5 ml Tween20 (0.05%)  
Adjust the pH to 8.0 with HCl and adjust the volume to 1L with deionised H2O.  
 
• Blocking solution  
5% of nonfat dried milk or BSA (Bovine Serum Albumine, Sigma) in 1x TBS-T. 
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• Amersham ECL Select Western Blotting Detection Reagent (GE Healthcare Life 
Sciences) 
 
 
 
 
• Membranes Stripping Solution (500 ml)  
- 3.76 g Tris-HCl (pH 6.7) (62.5 mM)  
- 10 g SDS (2%)  
- 3.5 ml Beta-mercaptoetanol (100 mM)  
Dissolve Tris and SDS in deionised H2O and adjust with HCl to pH 6.7. Add the 
mercaptoethanol and adjust volume to 500 ml. 
 
VI. Immunoprecipitation 
 
• Dynabeads® Protein G (Thermo Science) 
 
• Blocking solution  
Add 0.6g of BSA (Bovine Serum Albumine, Sigma) to 20 mL of PBS 1x. 
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Supplementary Figure 1 - GeneOntology of the PP1 merged interactome the most represented Molecular Functions. 
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 Supplementary Figure 2  - GeneOntology of of PP1α, PP1γ, Neurabin-1, Neurabin-2, Phactr3 and Cofilin merged 
interactome the most represented Molecular Functions. 
